Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.

作者信息

Jack Clifford R, Barnes Josephine, Bernstein Matt A, Borowski Bret J, Brewer James, Clegg Shona, Dale Anders M, Carmichael Owen, Ching Christopher, DeCarli Charles, Desikan Rahul S, Fennema-Notestine Christine, Fjell Anders M, Fletcher Evan, Fox Nick C, Gunter Jeff, Gutman Boris A, Holland Dominic, Hua Xue, Insel Philip, Kantarci Kejal, Killiany Ron J, Krueger Gunnar, Leung Kelvin K, Mackin Scott, Maillard Pauline, Malone Ian B, Mattsson Niklas, McEvoy Linda, Modat Marc, Mueller Susanne, Nosheny Rachel, Ourselin Sebastien, Schuff Norbert, Senjem Matthew L, Simonson Alix, Thompson Paul M, Rettmann Dan, Vemuri Prashanthi, Walhovd Kristine, Zhao Yansong, Zuk Samantha, Weiner Michael

机构信息

Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Department of Neurodegenerative Disease, Dementia Research Centre, Institute of Neurology, University College London, London, UK.

出版信息

Alzheimers Dement. 2015 Jul;11(7):740-56. doi: 10.1016/j.jalz.2015.05.002.

DOI:10.1016/j.jalz.2015.05.002

PMID:26194310

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4523217/

Abstract

INTRODUCTION

Alzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.

METHODS

We review the contributions of the MRI core from present and past cycles of ADNI (ADNI-1, -Grand Opportunity and -2). We also review plans for the future-ADNI-3.

RESULTS

Contributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials.

DISCUSSION

Over the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future.

摘要